Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Quick, cheap blood test predicts chance of surviving heart attack

12.11.2002


A rapid and inexpensive blood test that measures levels of a hormone predicted the long-term health of patients with heart attack and chest pain, according to a study published in today’s rapid access issue of Circulation: Journal of the American Heart Association.



This hormone – B-type natriuretic peptide (BNP) – is elevated when the heart is damaged. A fragment of this hormone called the N-terminal fragment (N-BNP), can provide a clearer picture of a patient’s likelihood of survival, more so than with current prognostic methods.

"In patients with acute coronary syndromes, N-BNP measurements taken early after admission identified patients at increased risk of early and late death," says senior author Kenneth Caidahl, M.D., Ph.D., a professor in the department of clinical physiology at the Sahlgrenska University Hospital in Göteborg, Sweden. "This relationship remained significant after adjusting for conventional risk markers. The most important finding was that N-BNP also predicted mortality among patients without clinical signs of left ventricular failure."


High levels of BNP are secreted by heart tissue when the heart is overloaded with pressure and its volume is expanded. By acting as a diuretic, the hormone helps return conditions to normal. In the last few years, testing in emergency departments for elevated levels of BNP has become a quick and accurate way to diagnose heart failure, allowing for earlier and better treatment. More recently, measuring the hormone has been shown to be a reliable way to predict future heart health in patients with heart attack or chest pain (angina). Newer studies show that N-BNP may provide prognostic information superior to BNP alone.

The prognosis of patients with heart attack or angina (also called acute coronary syndromes, or ACS) varies widely, and clinical, electrocardiographic and biochemical markers are used to identify high-risk patients who need aggressive intervention with a catheter procedure or surgery.

Caidahl and colleagues sought to clarify the role of N-BNP measurement in assessing ACS. They looked at 609 patients with ACS admitted to the coronary care unit of the Sahlgrenska University Hospital from September 1995 to February 2000. Death from all causes was the primary outcome measured, starting from the time of inclusion in the study to Sept. 15, 2001. Based on hospital records and personal interviews, the patients were classified as having or not having a medical history of heart attack, chest pain, congestive heart failure, diabetes and hypertension. Patients had N-BNP levels measured approximately three days after hospital admission, an echocardiographic study within five days of hospital admission, and left ventricular ejection fraction (LVEF) measured.

The study population consisted of 204 patients with ST-elevation heart attack, 220 with non-ST segment elevation heart attack, and 185 with unstable angina. After 51 months, with follow-up ranging from 19–72 months, 86 patients (14 percent) had died. Median N-BNP levels were significantly lower in long-term survivors than in patients dying (442 vs. 1306 pmol/L). In a statistical analysis, adjusting for patient age, heart failure status, and LVEF, N-BNP remained significantly associated with dying. Those in the highest group had twice the risk as those in the lowest group.

"N-BNP and BNP appear to be stronger predictors of short- and long-term mortality than conventional biochemical risk markers, including troponins, in acute coronary syndromes," says Caidahl. "This novel blood test is an important tool for risk stratification in acute coronary syndromes and may be measured routinely in this large and important patient group in the future. A method for rapid measurement of N-BNP has recently become commercially available."

In a related editorial, James A. de Lemos, M.D., of the University of Texas Southwestern Medical School in Dallas, and David A. Morrow, M.D., M.P.H., of Brigham and Women’s Hospital in Boston, emphasize the importance of this study because it went further than similar studies by directly addressing limitations of previous analyses. They write that previous studies were "substudies within randomized controlled trials and may have enrolled highly selected patients…" and "…did not include routine measurement of LVEF." Conversely, the authors also caution that "clinical investigation of BNP in general, and in particular its application in ACS, is still in its infancy." They note that the optimal timing of measurement is not yet clear, threshold values would be useful, and direct comparisons of BNP and N-BNP are needed.

Even so, the editorial authors say that the study "answers several critical questions and contributes to a consistent emerging message: in patients with ACS, BNP adds important prognostic information to clinical and laboratory variables…." They add that the "magnitude of risk relationship associated with BNP appears to be greater than that associated with most currently available markers. Clearly BNP is telling us something that we did not previously know about factors associated with risk in patients with ACS."



###
Co-authors are Torbjørn Omland, M.D., Ph.D.; Anita Persson, M.Sc.; Leong Ng, M.D., Ph.D.; Russel O’Brien, M.D.; Thomas Karlsson, M.Sc.; Johan Herlitz, M.D., Ph.D.; and Marianne Hartford, M.D., Ph.D.

CONTACT: For journal copies only,
please call: 214-706-1396
For other information, call:
Carole Bullock: 214-706-1279
Maggie Francis: 214-706-1397


Carole Bullock | EurekAlert!
Further information:
http://www.americanheart.org/

More articles from Health and Medicine:

nachricht NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)

nachricht High speed video recording precisely measures blood cell velocity
15.11.2017 | ITMO University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

Im Focus: Wrinkles give heat a jolt in pillared graphene

Rice University researchers test 3-D carbon nanostructures' thermal transport abilities

Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

NASA detects solar flare pulses at Sun and Earth

17.11.2017 | Physics and Astronomy

NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures

17.11.2017 | Health and Medicine

The importance of biodiversity in forests could increase due to climate change

17.11.2017 | Studies and Analyses

VideoLinks
B2B-VideoLinks
More VideoLinks >>>